Search Results

There are 6600 results for: content related to: Tolcapone added to levodopa in stable parkinsonian patients: A double-blind placebo-controlled study

  1. Catechol-O-methyltransferase inhibitors: Clinical potential in the treatment of Parkinson's disease

    Drug Development Research

    Volume 42, Issue 1, September 1997, Pages: 1–25, Jasper Dingemanse

    Article first published online : 6 DEC 1998, DOI: 10.1002/(SICI)1098-2299(199709)42:1<1::AID-DDR1>3.0.CO;2-I

  2. Tolcapone, a Selective Catechol-O-Methyltransferase Inhibitor for Treatment of Parkinson's Disease

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 19, Issue 1, January-February 1999, Pages: 6–20, David R. P. Guay

    Article first published online : 17 JAN 2012, DOI: 10.1592/phco.19.1.6.30516

  3. You have free access to this content
    Metabolism and excretion of tolcapone, a novel inhibitor of catechol-O-methyltransferase

    British Journal of Clinical Pharmacology

    Volume 48, Issue 4, October 1999, Pages: 513–520, Karin Jorga, Bärbel Fotteler, Peter Heizmann and Rodolfo Gasser

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.1999.00036.x

  4. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations

    Movement Disorders

    Volume 16, Issue 5, September 2001, Pages: 858–866, William Koller, Andrew Lees, Miroslava Doder, Mariese Hely and the Tolcapone/Pergolide Study Group

    Article first published online : 20 SEP 2001, DOI: 10.1002/mds.1175

  5. Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with “wearing-off” phenomenon: a multicentre, double-blind, randomized, placebo-controlled trial

    European Journal of Neurology

    Volume 4, Issue 4, July 1997, Pages: 333–341, V. V. Myllylä, M. Jackson, J. P. Larsen, H. Baas and Tolcapone International Parkinson's Disease Study (TIPS) Group I

    Article first published online : 20 JAN 2011, DOI: 10.1111/j.1468-1331.1997.tb00358.x

  6. You have free access to this content
    Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa.

    British Journal of Clinical Pharmacology

    Volume 40, Issue 3, Sep 1995, Pages: 253–262, J. Dingemanse, K. Jorga, G. Zurcher, M. Schmitt, G. Sedek, M. Da Prada and P. Van Brummelen

    Article first published online : 4 JUL 2012, DOI: 10.1111/j.1365-2125.1995.tb05781.x

  7. Interventions to Achieve Tonic Exposure to Levodopa: Delaying or Preventing the Onset of Motor Complications

    Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy

    Volume 19, Issue 11P2, November 1999, Pages: 169S–179S, Mark S. Luer

    Article first published online : 17 JAN 2012, DOI: 10.1592/phco.19.17.169S.30886

  8. The Disposition of the Tolcapone 3-O-Methylated Metabolite is Affected by the Route of Administration in Rats

    Journal of Pharmacy and Pharmacology

    Volume 46, Issue 7, July 1994, Pages: 571–574, TOMOO FUNAKI, HIDEKO ONODERA, NAOMI USHIYAMA, YUKO TSUKAMOTO, CHIEKO TAGAMI, HIDEO FUKAZAWA and ISAMI KURUMA

    Article first published online : 12 APR 2011, DOI: 10.1111/j.2042-7158.1994.tb03859.x

  9. Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients

    Movement Disorders

    Volume 14, Issue 1, January 1999, Pages: 38–44,

    Article first published online : 22 JAN 2001, DOI: 10.1002/1531-8257(199901)14:1<38::AID-MDS1008>3.0.CO;2-I

  10. Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease

    Intervention Review

    The Cochrane Library

    Katherine Deane, Sybille Spieker and Carl E Clarke

    Published Online : 18 OCT 2004, DOI: 10.1002/14651858.CD004554.pub2

  11. COMT inhibitors

    Movement Disorders

    Volume 17, Issue S4, July/August 2002, Pages: S45–S51,

    Article first published online : 29 JUL 2002, DOI: 10.1002/mds.5560

  12. 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease

    Synapse

    Volume 43, Issue 3, 1 March 2002, Pages: 201–207, Roberto Ceravolo, Paola Piccini, Dale L. Bailey, Karin M. Jorga, Helen Bryson and David J. Brooks

    Article first published online : 14 DEC 2001, DOI: 10.1002/syn.10034

  13. The effect of tolcapone on the pharmacokinetics of benserazide

    European Journal of Neurology

    Volume 6, Issue 2, March 1999, Pages: 211–219, Karin M. Jorga, Jan P. Larsen, Antonie Beiske, Michael Schleimer, Bärbel Fotteler, Monique Schmitt and Brit Moe

    Article first published online : 27 JUL 2007, DOI: 10.1111/j.1468-1331.1999.tb00015.x

  14. You have free access to this content
    Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies

    British Journal of Clinical Pharmacology

    Volume 49, Issue 1, January 2000, Pages: 39–48, Karin Jorga, Bärbel Fotteler, Ludger Banken, Paul Snell and Jean-Louis Steimer

    Article first published online : 24 DEC 2001, DOI: 10.1046/j.1365-2125.2000.00113.x

  15. Lack of an Effect of Madopar on the Disposition of Tolcapone and its 3-O-Methylated Metabolite in Rats

    Journal of Pharmacy and Pharmacology

    Volume 47, Issue 6, June 1995, Pages: 539–542, TOMOO FUNAKI, HIDEKO ONODERA, NAOMI USHIYAMA, YUKO TSUKAMOTO, CHIEKO TAGAMI, HIDEO FUKAZAWA and ISAMI KURUMA

    Article first published online : 12 APR 2011, DOI: 10.1111/j.2042-7158.1995.tb05846.x

  16. Evidence-Based Efficacy Comparison of Tolcapone and Entacapone as Adjunctive Therapy in Parkinson's Disease

    CNS Neuroscience & Therapeutics

    Volume 14, Issue 1, Spring 2008, Pages: 83–93, Andrew J. Lees

    Article first published online : 14 MAR 2008, DOI: 10.1111/j.1527-3458.2007.00035.x

  17. Minor Effect of Tolcapone, a Catechol- O-Methyltransferase Inhibitor, on Extracellular Dopamine Levels Modified by Amphetamine or Pargyline: A Microdialysis Study in Anaesthetized Rats

    Pharmacology & Toxicology

    Volume 78, Issue 6, June 1996, Pages: 392–396, Paivi Tuomainen, Martti Törnwall and Pekka T. Männistö

    Article first published online : 25 MAR 2009, DOI: 10.1111/j.1600-0773.1996.tb00224.x

  18. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson's disease patients

    Movement Disorders

    Volume 13, Issue 4, July 1998, Pages: 643–647, Robert A. Hauser, Eric Molho, Heidi Shale, Simon Pedder and Ernest E. Dorflinger

    Article first published online : 4 NOV 2004, DOI: 10.1002/mds.870130406

  19. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline

    Movement Disorders

    Volume 10, Issue 3, May 1995, Pages: 349–351, Dr. T. L. Davis, M. Roznoski and R. S. Burns

    Article first published online : 12 OCT 2004, DOI: 10.1002/mds.870100321

  20. Lack of Interaction between Tolcapone and Tolbutamide in Healthy Volunteers

    The Journal of Clinical Pharmacology

    Volume 40, Issue 5, May 2000, Pages: 544–551, Karin M. Jorga, Bärbel Fotteler, Rodolfo Gasser, Ludger Banken and Herbert Birnboeck

    Article first published online : 8 MAR 2013, DOI: 10.1177/00912700022009161